secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProPhase Labs, Inc. (PRPH)
CIK:        0000868278
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001493152-23-039993
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProPhase Labs Q3 net loss $5.1M; revenue down 65% to $8.4M; plans big capacity expansion
--------------------------------------------------------------------------------

- Q3 net loss $5.1M (-$0.30/sh) vs net income $1.0M ($0.06/sh) a year ago.
- Revenue fell to $8.4M from $24.2M; gross margin dropped to 27.8% from 49.5%.
- Adjusted EBITDA loss of $2.5M vs income of $6.3M in Q3 2022.
- Cash & equivalents $3.3M (Dec 31, 2022: $17.4M); working capital $33.4M.
- Pharmaloz capacity targets: $10M→$15M by year-end, over $75M in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/868278/000149315223039993/0001493152-23-039993-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/868278/000149315223039993/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-039993

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer